Psychopharmacology

A growing body of research has given us strategies at population, community, and clinical levels that can be put into practice. Details here.

A 20-year-old college sophomore with “depression and anxiety,” who is exercising ferociously and who is literally dying to lose more weight sets the stage.

The CDC and FDA have -- at last -- recognized that there might be something of a problem in the way opiates are prescribed!

When agitation and psychosis symptoms are severe, is an antipsychotic medication an option? Not always.

Improvement in depressive symptoms appears to have a salutary effect on sexual function.

Is clozapine still the gold standard for treatment-resistant schizophrenia?

What is the clinical response to the occasional presence of psychotic symptoms among patients with eating disorders?

Do atypical antipsychotics increase the risk of major malformations among exposed infants?

Clinical traditions are important, but they can become ossified as the “right way to treat addiction.” So, we need to turn a sharp, skeptical eye on treatment models.

Both the literature and clinical experience point to considerable risk in discontinuing antipsychotic treatment, for many chronically psychotic patients. Here's why.

The involvement of a psychiatrist early in the care of patients addicted to opioids may prevent further abuse. Here's why.

Reasons for the overall low rate of clozapine use brings to light questionable decisions on the part of policymakers

Setting the record straight on the burgeoning field of reproductive psychiatry.

A 19-year-old new patient comes to you wanting to discontinue all his childhood psychiatric medications. What is the best next step?

Setting the record straight on what the literature does and does not say about long-term use of antipsychotics.

A study of treatment tolerance and therapeutic response in children and adolescents with OCD.

Recent data show that widespread discrepancy exists between clinical guidelines and practice patterns for ADHD, dementia, and bipolar disorders.

Are you up-to-date on the risk of recurrent pneumonia in patients with schizophrenia when an antipsychotic is reintroduced?

Three new studies show the effects of depression-and its treatment-on the brain.

New evidence-coupled with advances in molecular biology-has afforded an unparalleled opportunity to move toward identifying potential new treatments for schizophrenia.

This method of administration can mitigate the psychotomimetic and dissociative effects of ketamine.

How do the 3 FDA-approved dopamine receptor partial agonists for the treatment of MDD and other psychiatric disorders stack up against each other?

A new finding that may help optimize the treatment of major depressive disorder.

Before flibanserin, there were no FDA-approved treatments for hypoactive sexual desire disorder. The authors clarify the intricacies of an HSDD diagnosis and discuss implications for treatment.